Edwards Lifesciences Corp (EW) reported strong Q4 2025 results with an 11.6% increase in sales and 10.7% for the full year, driven by robust growth in its TAVR and TMTT segments. Despite challenges like higher spending on patient access initiatives and one-time charges impacting EPS, the company maintains a positive outlook with confident 2026 sales and EPS guidance. CEO Bernard Zovighian and CFO Scott Ullem detailed strategic investments and market dynamics, particularly in TAVR and future growth opportunities like the LAA market.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Edwards Lifesciences Corp (EW) Q4 2025 Earnings Call Highlights: Strong Sales Growth Amidst Strategic Investments
Edwards Lifesciences Corp (EW) reported strong Q4 2025 results with an 11.6% increase in sales and 10.7% for the full year, driven by robust growth in its TAVR and TMTT segments. Despite challenges like higher spending on patient access initiatives and one-time charges impacting EPS, the company maintains a positive outlook with confident 2026 sales and EPS guidance. CEO Bernard Zovighian and CFO Scott Ullem detailed strategic investments and market dynamics, particularly in TAVR and future growth opportunities like the LAA market.